Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- GenEditBio Limited
- Study ID
- NCT07750678
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Corneal Abnormality
- Corneal Dystrophies
- Corneal Dystrophies, Hereditary
- Hereditary Corneal Dystrophy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- GEB-101 Injection — GENETICSingle intrastromal injection
Study Details
The goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-related Corneal Dystrophy
Key Dates
- First listed
- Aug 6, 2026
- Start date
- Aug 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Aug 31, 2027
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase 1GEB-101 dose 1 GEB-101 dose 2 GEB-101 dose 3 GEB-101 dose 4 GEB-101 dose 5
- Experimental: Phase 2GEB-101(RP2D)
Primary Outcome Measure
Incidence of DLTs [ Time Frame: 30 Days ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, Los Angeles (UCLA) | Los Angeles | California | 90095 | - |
Find similar trials in Los Angeles, CA
By research site